Osteoporosis | Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis

Osteoporosis research study

What is the primary objective of this study?

Teriparatide (PTH) is the only bone formation therapy that has been approved for the treatment of postmenopausal osteoporosis in Canada. Osteoporosis is currently diagnosed using a bone mineral density (BMD) scan, which measures the amount of mineral (calcium etc) in bones (the higher the amount of mineral, the lower the fracture risk). Although BMD is linked to bone strength and is used to measure fracture risk, it does not give information on bone structure (called bone geometry) which can also tell us a great deal about fracture risks. Clinical trials have shown that teriparatide increases BMD at the lumbar spine and total hip, while BMD at the forearm may decrease after 20 months of therapy. However, bone biopsies of the pelvis done on people taking teriparatide show improvement of bone geometry (ie bone thickness and increased trabeculae (small interconnecting rods of bone), suggesting that a change in bone geometry at the wrist may be occurring as well. Currently, there is a new technology, high resolution pQCT (HR-pQCT) that can assess bone geometry without a biopsy. Since bone strength is affected both by BMD and bone structure (as well as other material properties), our group is interested in examining changes in bone geometry at the radius and tibia in men and women with osteoporosis who receives 24 months of teriparatide therapy. The investigators believe that this new approach of measuring bone strength will help us better understand the mechanisms of therapeutic efficacy of teriparatide. In addition, measuring indices of bone strength such as the material composition (bone mineral content or BMD) and structural properties of bone (size and shape, and microarchitecture) may provide more data about the mechanisms of how teriparatide treatment can decrease fracture risk. In the end, this data will benefit and improve patient care by allowing us to show patients and their providers that whether BMD increases, decreases or stay the same, there are changes in their bone geometric structure with teriparatide therapy that increases bone strength.

Who is eligible to participate?

Inclusion Criteria: - History of fragility fracture OR - High risk for fractures OR - Very low BMD (T-score ≤ -2.5) OR - Failed or intolerant to bisphosphonates - Baseline serum levels of calcium, urate, ALP, PTH, creatinine and 25- hydroxyvitamin D [25(OH)D] must be within acceptable normal limits - Ability to obtain teriparatide (not supplied by study sponsor) Exclusion Criteria: - History of skeletal irradiation - Those at increased risk for osteosarcoma - Diagnosis of Paget's disease - History of primary hyperparathyroidism - Significant renal impairment - Vitamin D deficiency - On steroids or have other causes of secondary osteoporosis

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?


Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:TeriparatideForteo (teriparatide)pen daily for 24 months

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Forteo (teriparatide)postmenopausal women and men with osteoporosis Teriparatide is marketed as Forteo by Eli Lilly Teriparatide is not supplied (observational study)

Forteo (teriparatide) in AFFwomen who have experienced an atypical femur fracture (AFF) Teriparatide is not supplied (observational study)

Study Status


Start Date: November 2004

Completed Date: January 2020


Type: Observational


Primary Outcome: Change in cortical thickness at the radius and tibia as measured by high-resolution quantitative computer tomography (HR-pQCT)

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Angela m Cheung, MD, PhD

Lead Sponsor: University Health Network, Toronto


More information:

Discuss Osteoporosis